Please assess the completion status of the following clinical trial:

Trial Title: Phase 2 Study of ALN-RSV01 in Lung Transplant Patients Infected With Respiratory Syncytial Virus (RSV)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Single or bilateral lung transplant recipients~* Confirmed RSV infection~* Greater than 90 days post current lung transplant~* Rejection free for a minimum of 1 month~Exclusion Criteria:~* Antimicrobial therapy for known viral, bacterial, or fungal respiratory co-infection at the time of diagnosis~* Bronchiolitis obliterans syndrome (BOS) Grade 3 or any state BOS with FEV1 that has not been stable for at least 3 months~* Use of alemtuzumab within 9 months prior to screening; anti-thymocyte globulin(ATG) or thymoglobulin within 3 months of screening: concurrent use of \>= 0.3 mg/kg/day prednisone or equivalent as maintenance therapy~* active treament for acute graft rejection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): ALN-RSV01
- 2 (Type: PLACEBO_COMPARATOR): Normal saline

Based on this trial design, predict the completion outcome and termination type (if applicable).